Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
Status:
Withdrawn
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Our hypothesis is that budesonide will provide effective hepatic ISP that will replace
prednisone and allow lower systemic drug levels of FK, thus reducing the steroid- and
calcineurin-associated complications often observed in the OLT population. This study is
intended to investigate the therapeutic potential of this ISP combination.